Eight Allergy Companies to Watch in 2026
The allergy‑treatment landscape is moving from symptom relief to disease‑modifying therapies, with eight biotech firms leading the charge in 2026. Allergy Therapeutics secured German approval for its short‑course Grassmuno vaccine, while Aravax bolstered its board ahead of a phase 3 launch of PVX108 after a $42 million Series B. DBV Technologies reported positive phase 3 results for its VIASKIN peanut patch and is preparing a U.S. BLA, and IgGenix, Inimmune, Intrommune, Mabylon and Stallergenes Greer each announced key clinical or partnership milestones. The global allergy immunotherapy market is projected to grow from $1.8 billion in 2023 to $4.9 billion by 2033, attracting multibillion‑dollar interest from big pharma.
Mending University and Venture Capital Relations: Is It Possible to See Eye-to-Eye?
European university spin‑outs in deep‑tech and life sciences now represent a $398 billion asset pool, but collaboration with venture capitalists remains fraught. Tech transfer offices are tasked with bridging divergent goals—academia’s focus on discovery and publications versus VCs’ demand for speed...
Can Phage Therapy Answer the Booming Antibiotic Resistance Problem?
Antibiotic‑resistant infections cause nearly 5 million deaths annually, prompting renewed interest in bacteriophage therapy. Companies such as Armata Pharmaceuticals, TechnoPhage, and Locus Biosciences have reported positive clinical milestones, including Armata’s QIDP‑designated AP‑SA02 moving toward a phase 3 trial and TechnoPhage’s phase 2b study...
Amgen Pipeline’s Next Growth Cycle: Replacing Its Old Blockbusters
Amgen posted $36.8 billion in 2025 revenue, a 10% year‑on‑year rise, but its legacy blockbusters such as Enbrel, Xgeva and Otezla are under pressure from biosimilars and U.S. pricing reforms. Growth is now being driven by cardiovascular drugs, rare‑disease assets acquired...
Top Biotech Deals in March 2026
Biotech M&A activity peaked in March 2026 with twelve announced deals, eight of which were multi‑billion‑dollar transactions. The largest was Lilly’s $7.8 billion acquisition of Centessa, adding an orexin‑receptor‑2 program for narcolepsy. Other marquee deals included Biogen’s $5.6 billion purchase of Apellis, Merck’s...
Multi-Agent AI Delivers Reliable and Scalable Insights for Single-Cell Omics
Nygen Analytics, a Lund‑based startup founded by computational genomics expert Parashar Dhapola, is deploying multi‑agent AI to streamline single‑cell omics analysis. The platform automates cell‑type annotation, handling millions of cells while reducing error rates that can misguide drug discovery. By...
Extracellular Vesicles: A Growing Pipeline Still Searching for Validation
Extracellular vesicles (EVs), once hailed as natural delivery vehicles, have generated a sizable pipeline but no approved therapeutics yet. More than 90 clinical studies are evaluating both native MSC‑derived vesicles and engineered platforms for regeneration, gene editing, and vaccines. Companies...
The Future of Cell & Gene Therapy: Key Trends to Watch
Cell and gene therapy is transitioning from ex vivo manufacturing toward in vivo delivery, driven by advances in vector engineering and lipid‑nanoparticle platforms. Major pharma players have launched billion‑dollar acquisitions to secure in vivo CAR‑T and RNA technologies, while the stem‑cell market is...
Nionyx Bio’s Kidney Gene Therapy Wins the 2026 BIO-Europe Spring Startup Spotlight
Nionyx Bio, led by CEO Magdalena Tyrpien, captured first place in the 2026 BIO‑Europe Spring Startup Spotlight in Lisbon. The company focuses on a proprietary adeno‑associated virus (AAV) capsid platform paired with a Kidney Atlas to deliver gene therapies for...
Portugal: Will the Life Science Sector See Upswing Amid Funding Worries?
Portugal’s life‑science sector generated €29.7 billion ($34.4 billion) in gross value added in 2024, employing over 268,000 people across 124,000 firms. The ecosystem gained visibility after hosting BIO‑Europe Spring, showcasing biotech startups, research parks like Biocant, and major deals such as BioNTech’s...
Six Biotech Companies in Berlin to Watch in 2026
Berlin’s biotech sector is gaining global traction, highlighted by six innovative firms. 3B Pharmaceuticals secured a Novartis licensing deal for its FAP‑2286 radioligand and is collaborating on an astatine‑211 candidate. Ariceum Therapeutics dosed its first patient in a phase 1/2 trial...
Next-Generation Allosteric Modulators: A Glance at the Biotech Pipeline in 2026
Allosteric modulators, which fine‑tune protein activity rather than fully activate or inhibit, are gaining traction across neurology, oncology and immunology. Recent pipeline highlights include Rapport Therapeutics’ RAP‑219 achieving a 77.8% seizure reduction in a phase 2a study, Atavistik Bio’s AKT1‑selective inhibitor...
Biotech in New Jersey, Seven Companies Leading the Charge
New Jersey remains a heavyweight pharma cluster, home to giants like Johnson & Johnson and Merck, while nurturing a growing biotech startup scene. Companies such as ArrePath, BioAegis, Celularity, Enalare, EpiBone, Inaedis and Rocket Pharmaceuticals are advancing AI‑driven antibiotics, plasma‑protein...
HaemaLogiX – Precision Immunotherapy for Multiple Myeloma
HaemaLogiX, an Australian clinical‑stage biotech, is developing precision immunotherapies for multiple myeloma by targeting novel antigens KMA and LMA that appear only on malignant plasma cells. Peer‑reviewed research validates these targets, allowing the company to spare healthy plasma cells and...
GSK’s Two-Speed Strategy: Broad Sourcing and Selective Bets
GSK has accelerated its pipeline build‑out by pairing broad early‑stage partnerships with selective, later‑stage acquisitions such as the up‑to‑$950 million purchase of 35Pharma’s pulmonary‑hypertension candidate HS235. After spinning off Haleon, the company now leans on specialty medicines—accounting for over 40% of...
